FDA issues guidance on rare disease drug development

FDA issued draft guidance to advise companies developing candidates to treat rare diseases.

While the agency does not require companies to conduct natural history studies, it noted that natural history data can inform several aspects of a sponsor's clinical development program including the definition of a study's disease population and duration, the selection of appropriate outcome measures and the development of new biomarkers. ...